NASDAQ:SGMO - Sangamo Therapeutics Stock Price, Price Target & More

$16.25 -1.05 (-6.07 %)
(As of 04/26/2018 04:00 PM ET)
Previous Close$16.25
Today's Range$16.10 - $16.75
52-Week Range$4.25 - $27.50
Volume7.90 million shs
Average Volume2.26 million shs
Market Capitalization$1.54 billion
P/E Ratio-23.21
Dividend YieldN/A
Beta2.8

About Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics logoSangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Receive SGMO News and Ratings via Email

Sign-up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGMO
CUSIP80067710
Phone510-970-6000

Debt

Debt-to-Equity Ratio0.13%
Current Ratio5.54%
Quick Ratio5.54%

Price-To-Earnings

Trailing P/E Ratio-23.21
Forward P/E Ratio-108.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$36.57 million
Price / Sales38.37
Cash FlowN/A
Price / CashN/A
Book Value$2.22 per share
Price / Book7.32

Profitability

EPS (Most Recent Fiscal Year)($0.70)
Net Income$-54,560,000.00
Net Margins-149.23%
Return on Equity-31.44%
Return on Assets-22.13%

Miscellaneous

Employees182
Outstanding Shares86,340,000

How to Become a New Pot Stock Millionaire

Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics Inc (NASDAQ:SGMO) issued its quarterly earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.03. The biopharmaceutical company earned $13.08 million during the quarter, compared to analysts' expectations of $11.10 million. Sangamo Therapeutics had a negative net margin of 149.23% and a negative return on equity of 31.44%. Sangamo Therapeutics's quarterly revenue was up 46.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.14) EPS. View Sangamo Therapeutics' Earnings History.

When is Sangamo Therapeutics' next earnings date?

Sangamo Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Sangamo Therapeutics.

What price target have analysts set for SGMO?

5 Wall Street analysts have issued 1 year price objectives for Sangamo Therapeutics' shares. Their predictions range from $8.00 to $30.00. On average, they expect Sangamo Therapeutics' stock price to reach $22.20 in the next year. View Analyst Ratings for Sangamo Therapeutics.

What are Wall Street analysts saying about Sangamo Therapeutics stock?

Here are some recent quotes from research analysts about Sangamo Therapeutics stock:
  • 1. Wedbush analysts commented, "We traveled with VBI management last week in Boston and noted good reception and enthusiasm around the lead program Sci-B-Vac for Hepatitis B. Enrollment is proceeding well in Phase 3, which we anticipate could be complete during 2Q18. VBI still expects top-line Phase 3 data in mid-2019, which we expect to easily show non- inferiority to GSK’s Engerix-B, and which could show superiority in adults age 45 or older. Interestingly, VBI will also measure seroprotection after 2 doses of Sc-B-Vac vs 3 doses of Engerix-B, which we expect to be positive for Engerix-B as well. In our view, over the long-term, Sci-B-Vac could show a profile suggesting 2 dose protection in patients of all ages, greatly expanding the market opportunity, which we conservatively project to be $370M WW." (3/13/2018)
  • 2. According to Zacks Investment Research, "Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States. " (1/5/2018)

Are investors shorting Sangamo Therapeutics?

Sangamo Therapeutics saw a increase in short interest in April. As of April 13th, there was short interest totalling 11,950,598 shares, an increase of 20.7% from the March 30th total of 9,901,110 shares. Based on an average trading volume of 2,446,250 shares, the short-interest ratio is presently 4.9 days. Approximately 14.1% of the shares of the stock are sold short.

Who are some of Sangamo Therapeutics' key competitors?

Who are Sangamo Therapeutics' key executives?

Sangamo Therapeutics' management team includes the folowing people:
  • Alexander D. Macrae Ph.D., President, Chief Executive Officer, Director (Age 54)
  • Kathy Y. Yi, Chief Financial Officer, Senior Vice President (Age 45)
  • Heather D. Turner, Senior Vice President, General Counsel (Age 43)
  • Edward R. Conner M.D., Senior Vice President and Chief Medical Officer (Age 44)
  • Curt Herberts III, Senior Vice President and Chief Business Officer (Age 36)
  • Roger Jeffs Ph.D., Director
  • Joseph S. Zakrzewski, Director (Age 54)
  • Robert F. Carey, Independent Director (Age 58)
  • Stephen G. Dilly M.D. Ph.D., Independent Director (Age 57)
  • Steven J. Mento Ph.D., Independent Director (Age 65)

Has Sangamo Therapeutics been receiving favorable news coverage?

Headlines about SGMO stock have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sangamo Therapeutics earned a media sentiment score of 0.13 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.01 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sangamo Therapeutics' stock price today?

One share of SGMO stock can currently be purchased for approximately $16.25.

How big of a company is Sangamo Therapeutics?

Sangamo Therapeutics has a market capitalization of $1.54 billion and generates $36.57 million in revenue each year. The biopharmaceutical company earns $-54,560,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Sangamo Therapeutics employs 182 workers across the globe.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 501 CANAL BLVD, RICHMOND CA, 94804. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]


MarketBeat Community Rating for Sangamo Therapeutics (SGMO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  237 (Vote Outperform)
Underperform Votes:  221 (Vote Underperform)
Total Votes:  458
MarketBeat's community ratings are surveys of what our community members think about Sangamo Therapeutics and other stocks. Vote "Outperform" if you believe SGMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGMO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sangamo Therapeutics (NASDAQ:SGMO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Sangamo Therapeutics in the last 12 months. Their average twelve-month price target is $22.20, suggesting that the stock has a possible upside of 36.62%. The high price target for SGMO is $30.00 and the low price target for SGMO is $8.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.832.60
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.20$22.20$19.80$15.00
Price Target Upside: 36.62% upside14.62% downside10.92% upside0.33% upside

Sangamo Therapeutics (NASDAQ:SGMO) Consensus Price Target History

Price Target History for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ:SGMO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/13/2018WedbushReiterated RatingHold$8.00MediumView Rating Details
2/25/2018BarclaysReiterated RatingBuy$30.00LowView Rating Details
2/23/2018Jefferies GroupReiterated RatingBuyLowView Rating Details
1/3/2018Piper JaffraySet Price TargetBuy$25.00HighView Rating Details
9/5/2017Wells FargoReiterated RatingOutperform$20.00 -> $30.00LowView Rating Details
3/22/2017CowenReiterated RatingBuyHighView Rating Details
8/4/2016Janney Montgomery ScottDowngradeBuy -> Neutral$15.00 -> $8.00N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Sangamo Therapeutics (NASDAQ:SGMO) Earnings History and Estimates Chart

Earnings by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ:SGMO) Earnings Estimates

2018 EPS Consensus Estimate: $0.01
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.08)($0.08)($0.08)
Q2 20181$0.03$0.03$0.03
Q3 20181$0.03$0.03$0.03
Q4 20181$0.03$0.03$0.03

Sangamo Therapeutics (NASDAQ SGMO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018($0.16)N/AView Earnings Details
2/22/2018Q4 2017($0.18)($0.1540)$11.10 million$13.08 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.19)($0.15)$10.37 million$11.81 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.23)($0.17)$5.82 million$8.30 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.26)($0.23)$4.14 million$3.40 millionViewN/AView Earnings Details
2/28/2017Q416($0.26)($0.14)$3.91 million$8.90 millionViewListenView Earnings Details
10/26/2016Q316($0.25)($0.27)$4.24 million$2.82 millionViewListenView Earnings Details
8/3/2016Q216($0.24)($0.38)$5.38 million$3.70 millionViewN/AView Earnings Details
5/2/2016Q116($0.24)($0.23)$5.49 million$3.94 millionViewN/AView Earnings Details
2/9/2016Q415($0.21)($0.20)$9.86 million$9.10 millionViewN/AView Earnings Details
10/28/2015Q315($0.25)($0.13)$13.09 million$8.57 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.17)$14.72 million$8.36 millionViewListenView Earnings Details
4/22/2015Q115($0.13)($0.08)$12.50 million$13.50 millionViewListenView Earnings Details
2/10/2015Q414($0.09)($0.06)$14.50 million$15.00 millionViewN/AView Earnings Details
10/22/2014Q314($0.04)($0.11)$8.27 million$12.40 millionViewListenView Earnings Details
7/23/2014Q214($0.14)($0.10)$7.84 million$10.38 millionViewListenView Earnings Details
5/6/2014Q114($0.13)($0.12)$6.59 million$8.10 millionViewListenView Earnings Details
2/11/2014Q413($0.10)($0.13)$8.90 million$6.90 millionViewListenView Earnings Details
10/23/2013Q313($0.11)($0.11)$5.52 million$5.70 millionViewN/AView Earnings Details
7/24/2013Q2 2013($0.12)($0.10)$4.77 million$6.90 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.17)($0.13)$3.79 million$4.60 millionViewN/AView Earnings Details
2/6/2013Q4 2012($0.12)($0.07)$5.95 million$8.93 millionViewN/AView Earnings Details
10/24/2012Q312($0.14)($0.11)$3.80 million$4.90 millionViewN/AView Earnings Details
7/25/2012($0.15)($0.11)ViewN/AView Earnings Details
5/2/2012($0.16)($0.14)ViewN/AView Earnings Details
2/8/2012Q4 2011($0.13)($0.12)ViewN/AView Earnings Details
10/25/2011($0.16)($0.18)ViewN/AView Earnings Details
7/27/2011($0.16)($0.20)ViewN/AView Earnings Details
4/26/2011($0.17)($0.21)ViewN/AView Earnings Details
2/2/2011($0.19)($0.18)ViewN/AView Earnings Details
10/27/2010Q3 2010($0.15)($0.19)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.08)($0.09)ViewN/AView Earnings Details
5/3/2010Q1 2010($0.09)ViewN/AView Earnings Details
2/3/2010Q4 2009($0.07)($0.05)ViewN/AView Earnings Details
11/4/2009Q3 2009($0.13)($0.12)ViewN/AView Earnings Details
7/29/2009Q2 2009($0.15)($0.11)ViewN/AView Earnings Details
4/29/2009Q1 2009($0.10)($0.17)ViewN/AView Earnings Details
2/4/2009Q4 2008($0.15)($0.06)ViewN/AView Earnings Details
10/29/2008Q3 2008($0.17)($0.15)ViewN/AView Earnings Details
7/23/2008Q2 2008($0.17)($0.18)ViewN/AView Earnings Details
4/30/2008Q1 2008($0.16)($0.20)ViewN/AView Earnings Details
2/5/2008Q4 2007($0.12)($0.17)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Sangamo Therapeutics (NASDAQ:SGMO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Sangamo Therapeutics (NASDAQ SGMO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 65.16%
Insider Trading History for Sangamo Therapeutics (NASDAQ:SGMO)
Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ SGMO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Kathy YiCFOSell5,000$19.83$99,150.0012,250View SEC Filing  
4/13/2018Curt A Herberts IIIVPSell8,163$20.00$163,260.0022,788View SEC Filing  
4/6/2018Edward R. ConnerVPSell5,000$17.41$87,050.00View SEC Filing  
4/2/2018Curt A Herberts IIIVPSell2,278$18.30$41,687.40View SEC Filing  
4/2/2018Steven J MentoDirectorSell7,215$18.40$132,756.00View SEC Filing  
3/15/2018Kathy YiCFOSell5,000$25.56$127,800.0012,250View SEC Filing  
3/6/2018Edward R. ConnerVPSell5,000$24.78$123,900.00View SEC Filing  
3/1/2018Curt A Herberts IIIVPSell15,000$23.06$345,900.0014,796View SEC Filing  
3/1/2018Steven J MentoDirectorSell9,433$23.27$219,505.918,480View SEC Filing  
2/26/2018Saira RamasastryDirectorSell9,450$24.88$235,116.009,450View SEC Filing  
2/6/2018Edward R. ConnerVPSell5,000$18.49$92,450.00View SEC Filing  
2/1/2018Curt A Herberts IIIVPSell15,000$20.59$308,850.0029,625View SEC Filing  
2/1/2018Steven J MentoDirectorSell11,520$20.59$237,196.805,000View SEC Filing  
1/8/2018Edward R. ConnerVPSell5,000$17.11$85,550.00View SEC Filing  
1/3/2018Curt A Herberts IIIVPSell15,000$17.26$258,900.0013,015View SEC Filing  
12/6/2017Edward R ConnerVPSell5,000$16.24$81,200.005,000View SEC Filing  
12/4/2017Curt A Herberts IIIVPSell11,803$18.00$212,454.0027,636View SEC Filing  
12/1/2017Curt A. Herberts IIIVPSell16,630$16.13$268,241.90View SEC Filing  
11/17/2017Saira RamasastryDirectorSell5,000$14.67$73,350.005,000View SEC Filing  
10/2/2017Curt A Herberts IIIVPSell15,000$15.25$228,750.00View SEC Filing  
9/20/2017William R RingoDirectorSell31,000$14.37$445,470.0031,800View SEC Filing  
9/1/2017Curt A Herberts IIIVPSell15,000$15.00$225,000.0015,833View SEC Filing  
8/14/2017Curt A Herberts IIIVPSell11,474$10.44$119,788.5623,991View SEC Filing  
7/14/2017Curt A Herberts IIIVPSell15,000$10.00$150,000.0035,517View SEC Filing  
6/1/2017Curt A. Herberts IIIVPSell2,000$6.80$13,600.00View SEC Filing  
5/12/2017Curt A. Herberts IIIVPSell2,639$8.02$21,164.78View SEC Filing  
8/1/2015Ra Capital Management, LlcMajor ShareholderSell27,770$12.82$356,011.40View SEC Filing  
7/30/2015Ra Capital Management, LlcMajor ShareholderSell109,590$12.42$1,361,107.80View SEC Filing  
7/29/2015Ra Capital Management, LlcMajor ShareholderSell1,407$12.41$17,460.87View SEC Filing  
7/28/2015Ra Capital Management, LlcMajor ShareholderSell60,081$12.11$727,580.91View SEC Filing  
7/25/2015Ra Capital Management, LlcMajor ShareholderSell47,429$12.31$583,850.99View SEC Filing  
7/24/2015Ra Capital Management, LlcMajor ShareholderSell124,050$12.28$1,523,334.00View SEC Filing  
7/17/2015Ra Capital Management, LlcMajor ShareholderBuy37,215$12.26$456,255.90View SEC Filing  
7/15/2015Edward O Lanphier IICEOSell25,000$10.43$260,750.00View SEC Filing  
7/13/2015Henry Ward WolffCFOSell12,000$10.00$120,000.00View SEC Filing  
7/1/2015Ra Capital Management, LlcMajor ShareholderSell82,700$16.01$1,324,027.00View SEC Filing  
6/16/2015Ra Capital Management, LlcMajor ShareholderSell250,500$16.55$4,145,775.00View SEC Filing  
6/9/2015Ra Capital Management, LlcMajor ShareholderSell83,500$15.50$1,294,250.00View SEC Filing  
6/6/2015Ra Capital Management, LlcMajor ShareholderSell135,101$14.29$1,930,593.29View SEC Filing  
6/5/2015Dale G AndoCMOSell15,000$12.29$184,350.00View SEC Filing  
6/5/2015Ra Capital Management, LlcMajor ShareholderSell115,102$14.13$1,626,391.26View SEC Filing  
6/4/2015Ra Capital Management, LlcMajor ShareholderSell70,640$13.10$925,384.00View SEC Filing  
6/3/2015Ra Capital Management, LlcMajor ShareholderSell76,833$12.86$988,072.38View SEC Filing  
6/3/2015William R RingoDirectorSell2,200$12.44$27,368.00View SEC Filing  
6/1/2015Philip D GregorySVPSell15,000$12.39$185,850.00View SEC Filing  
5/30/2015Ra Capital Management, LlcMajor ShareholderSell65,884$13.40$882,845.60View SEC Filing  
5/29/2015Ra Capital Management, LlcMajor ShareholderSell155,675$13.53$2,106,282.75View SEC Filing  
5/28/2015Ra Capital Management, LlcMajor ShareholderSell148,689$13.43$1,996,893.27View SEC Filing  
5/27/2015Ra Capital Management, LlcMajor ShareholderSell263,437$13.55$3,569,571.35View SEC Filing  
5/23/2015Ra Capital Management, LlcMajor ShareholderSell51,597$13.27$684,692.19View SEC Filing  
5/22/2015Ra Capital Management, LlcMajor ShareholderSell56,396$13.56$764,729.76View SEC Filing  
5/13/2015Ra Capital Management, LlcMajor ShareholderSell56,060$13.12$735,507.20View SEC Filing  
5/12/2015Ra Capital Management, LlcMajor ShareholderSell29,659$13.03$386,456.77View SEC Filing  
5/8/2015Ra Capital Management, LlcMajor ShareholderSell83,300$12.40$1,032,920.00View SEC Filing  
5/7/2015Ra Capital Management, LlcMajor ShareholderBuy35,736$12.09$432,048.24View SEC Filing  
5/5/2015Dale G AndoCMOSell15,000$12.29$184,350.00View SEC Filing  
5/4/2015William R RingoDirectorSell3,000$12.98$38,940.00View SEC Filing  
4/30/2015Ra Capital Management, LlcMajor ShareholderBuy124,500$13.45$1,674,525.00View SEC Filing  
4/28/2015Ra Capital Management, LlcMajor ShareholderBuy74,844$13.29$994,676.76View SEC Filing  
4/25/2015Ra Capital Management, LlcMajor ShareholderBuy166,000$13.63$2,262,580.00View SEC Filing  
4/22/2015Ra Capital Management, LlcMajor ShareholderSell352,750$14.86$5,241,865.00View SEC Filing  
4/17/2015Ra Capital Management, LlcMajor ShareholderBuy41,500$14.02$581,830.00View SEC Filing  
4/16/2015Ra Capital Management, LlcMajor ShareholderSell21,829$14.09$307,570.61View SEC Filing  
4/15/2015Edward O Lanphier IICEOSell25,000$15.33$383,250.00View SEC Filing  
4/15/2015Ra Capital Management, LlcMajor ShareholderBuy21,829$13.16$287,269.64View SEC Filing  
4/14/2015Ra Capital Management, LlcMajor ShareholderSell3,055$14.78$45,152.90View SEC Filing  
4/11/2015Ra Capital Management, LlcMajor ShareholderBuy116,992$14.48$1,694,044.16View SEC Filing  
4/10/2015Henry Ward WolffCFOSell12,000$15.31$183,720.00View SEC Filing  
4/10/2015Ra Capital Management, LlcMajor ShareholderBuy83,000$14.91$1,237,530.00View SEC Filing  
4/9/2015Ra Capital Management, LlcMajor ShareholderSell69,856$16.27$1,136,557.12View SEC Filing  
4/8/2015Ra Capital Management, LlcMajor ShareholderBuy121,876$15.49$1,887,859.24View SEC Filing  
4/7/2015Ra Capital Management, LlcMajor ShareholderBuy33,667$15.42$519,145.14View SEC Filing  
4/6/2015Dale G AndoCMOSell15,000$14.94$224,100.00View SEC Filing  
4/6/2015William R RingoDirectorSell2,200$14.95$32,890.00View SEC Filing  
4/4/2015Ra Capital Management, LlcMajor ShareholderBuy179,031$15.38$2,753,496.78View SEC Filing  
4/3/2015Ra Capital Management, LlcMajor ShareholderBuy195,126$16.61$3,241,042.86View SEC Filing  
4/1/2015Philip D GregorySVPSell15,000$15.15$227,250.00View SEC Filing  
4/1/2015Ra Capital Management, LlcMajor ShareholderSell250,000$18.01$4,502,500.00View SEC Filing  
3/28/2015Ra Capital Management, LlcMajor ShareholderBuy84,000$17.10$1,436,400.00View SEC Filing  
3/27/2015Ra Capital Management, LlcMajor ShareholderBuy256,187$17.65$4,521,700.55View SEC Filing  
3/26/2015Ra Capital Management, LlcMajor ShareholderBuy210,013$18.14$3,809,635.82View SEC Filing  
3/25/2015Ra Capital Management, LlcMajor ShareholderBuy84,000$19.42$1,631,280.00View SEC Filing  
3/21/2015Ra Capital Management, LlcMajor ShareholderBuy101,808$21.22$2,160,365.76View SEC Filing  
3/19/2015Henry Ward WolffCFOSell10,000$18.00$180,000.00View SEC Filing  
3/19/2015Ra Capital Management, LlcMajor ShareholderSell17,808$24.28$432,378.24View SEC Filing  
3/18/2015Ra Capital Management, LlcMajor ShareholderSell84,000$23.74$1,994,160.00View SEC Filing  
3/17/2015Ra Capital Management, LlcMajor ShareholderBuy52,161$23.02$1,200,746.22View SEC Filing  
3/16/2015Edward O Lanphier IICEOSell25,000$17.29$432,250.00View SEC Filing  
3/13/2015Ra Capital Management, LlcMajor ShareholderBuy71,319$22.76$1,623,220.44View SEC Filing  
3/12/2015Ra Capital Management, LlcMajor ShareholderSell123,480$23.40$2,889,432.00View SEC Filing  
3/10/2015Ra Capital Management, LlcMajor ShareholderBuy12,522$22.30$279,240.60View SEC Filing  
3/7/2015Ra Capital Management, LlcMajor ShareholderBuy258,377$22.25$5,748,888.25View SEC Filing  
3/6/2015Ra Capital Management, LlcMajor ShareholderSell61,483$24.10$1,481,740.30View SEC Filing  
3/3/2015Ra Capital Management, LlcMajor ShareholderSell84,000$18.21$1,529,640.00View SEC Filing  
3/3/2015William R RingoDirectorSell2,200$17.21$37,862.00View SEC Filing  
3/2/2015Philip D GregorySVPSell15,000$17.26$258,900.00View SEC Filing  
2/28/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.10$760,200.00View SEC Filing  
2/27/2015Ra Capital Management, LlcMajor ShareholderSell32,196$19.37$623,636.52View SEC Filing  
2/26/2015Ra Capital Management, LlcMajor ShareholderBuy74,194$19.57$1,451,976.58View SEC Filing  
2/20/2015Ra Capital Management, LlcMajor ShareholderSell35,319$18.40$649,869.60View SEC Filing  
2/19/2015Ra Capital Management, LlcMajor ShareholderSell6,720$18.51$124,387.20View SEC Filing  
2/18/2015Ra Capital Management, LlcMajor ShareholderSell11,172$18.11$202,324.92View SEC Filing  
2/14/2015Ra Capital Management, LlcMajor ShareholderSell15,380$18.61$286,221.80View SEC Filing  
2/13/2015Ra Capital Management, LlcMajor ShareholderSell15,409$18.46$284,450.14View SEC Filing  
2/12/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.04$757,680.00View SEC Filing  
2/12/2015Saira RamasastryDirectorSell10,000$15.00$150,000.00View SEC Filing  
2/11/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$19.65$825,300.00View SEC Filing  
2/7/2015Ra Capital Management, LlcMajor ShareholderSell34,688$18.52$642,421.76View SEC Filing  
2/6/2015Ra Capital Management, LlcMajor ShareholderSell7,312$18.42$134,687.04View SEC Filing  
2/5/2015Dale G AndoCMOSell15,000$12.93$193,950.00View SEC Filing  
2/5/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.23$765,660.00View SEC Filing  
2/3/2015William R RingoDirectorSell2,200$12.70$27,940.00View SEC Filing  
2/2/2015Philip D GregorySVPSell15,000$12.86$192,900.00View SEC Filing  
1/16/2015Edward O Lanphier IICEOSell25,000$14.22$355,500.00View SEC Filing  
1/12/2015Henry Ward WolffCFOSell12,000$15.87$190,440.00View SEC Filing  
1/5/2015Dale G AndoCMOSell15,000$15.19$227,850.00View SEC Filing  
1/5/2015William R RingoDirectorSell2,200$15.20$33,440.00View SEC Filing  
12/15/2014Edward O Lanphier IICEOSell25,000$15.40$385,000.00View SEC Filing  
12/15/2014John William LarsonDirectorSell10,000$16.28$162,800.00View SEC Filing  
12/9/2014John William LarsonDirectorSell10,000$12.00$120,000.00View SEC Filing  
12/1/2014Philip D GregorySVPSell15,000$11.68$175,200.00View SEC Filing  
11/17/2014Edward O Lanphier IICEOSell25,000$11.23$280,750.00View SEC Filing  
11/12/2014John William LarsonDirectorSell10,000$12.00$120,000.00View SEC Filing  
11/3/2014Philip D GregorySVPSell15,000$11.91$178,650.00View SEC Filing  
10/28/2014John William LarsonDirectorSell10,000$12.02$120,200.00View SEC Filing  
10/10/2014Henry Ward WolffCFOSell2,000$10.10$20,200.00View SEC Filing  
10/6/2014Dale G AndoCMOSell15,000$10.72$160,800.00View SEC Filing  
10/1/2014Philip D GregorySVPSell15,000$10.80$162,000.00View SEC Filing  
9/15/2014Edward O Lanphier IICEOSell25,000$12.14$303,500.00View SEC Filing  
9/10/2014Henry Ward WolffCFOSell2,000$12.31$24,620.00View SEC Filing  
9/5/2014Dale G AndoCMOSell15,000$12.20$183,000.00View SEC Filing  
9/4/2014John William LarsonDirectorSell10,000$12.81$128,100.00View SEC Filing  
8/15/2014Edward O Lanphier IICEOSell25,000$13.95$348,750.00View SEC Filing  
8/11/2014Henry Ward WolffCFOSell10,000$14.17$141,700.00View SEC Filing  
8/5/2014Dale G AndoCMOSell15,000$12.99$194,850.00View SEC Filing  
8/4/2014John William LarsonDirectorSell10,000$12.56$125,600.00View SEC Filing  
8/1/2014Philip D GregorySVPSell15,000$12.54$188,100.00View SEC Filing  
7/18/2014Edward O Lanphier IICEOSell25,000$12.16$304,000.00View SEC Filing  
7/10/2014Henry Ward WolffCFOSell15,000$13.26$198,900.00View SEC Filing  
7/1/2014Philip D GregorySVPSell15,000$15.66$234,900.00View SEC Filing  
6/23/2014Saira RamasastryDirectorSell5,550$15.53$86,191.50View SEC Filing  
6/16/2014Edward O Lanphier IICEOSell25,000$16.41$410,250.00View SEC Filing  
6/10/2014Henry Ward WolffCFOSell15,000$15.62$234,300.00View SEC Filing  
6/2/2014Philip D GregorySVPSell15,000$12.85$192,750.00View SEC Filing  
5/15/2014Edward Lanphier IICEOSell25,000$13.14$328,500.00295,000View SEC Filing  
5/1/2014Philip GregorySVPSell15,000$13.68$205,200.00109,347View SEC Filing  
4/28/2014Dale AndoCMOSell15,000$13.64$204,600.0097,015View SEC Filing  
4/28/2014John William LarsonDirectorSell10,000$13.48$134,800.00218,160View SEC Filing  
4/15/2014Edward Lanphier IICEOSell25,000$14.20$355,000.00295,000View SEC Filing  
4/10/2014Henry Ward WolffCFOSell15,000$15.72$235,800.00225,347View SEC Filing  
3/26/2014Dale AndoCMOSell15,000$18.65$279,750.0097,015View SEC Filing  
3/21/2014Philip GregoryInsiderSell15,000$22.38$335,700.00109,347View SEC Filing  
3/17/2014Edward Lanphier IICEOSell50,000$23.22$1,161,000.00295,000View SEC Filing  
3/17/2014Saira RamasastryDirectorSell10,000$23.26$232,600.00View SEC Filing  
3/14/2014Steven MentoDirectorSell6,103$22.77$138,965.3123,563View SEC Filing  
2/18/2014Edward Lanphier IICEOSell50,000$18.09$904,500.00295,000View SEC Filing  
1/27/2014Dale AndoCMOSell15,000$18.58$278,700.0097,015View SEC Filing  
1/10/2014Henry Ward WolffCFOSell10,000$18.69$186,900.00227,347View SEC Filing  
1/2/2014Philip GregoryVPSell15,000$13.56$203,400.00109,347View SEC Filing  
12/26/2013Dale AndoCMOSell15,000$14.37$215,550.0097,015View SEC Filing  
11/15/2013Edward Lanphier IICEOSell25,000$10.11$252,750.00330,000View SEC Filing  
11/5/2013Philip D GregoryVPSell15,000$9.60$144,000.00View SEC Filing  
10/28/2013Dale G AndoCMOSell15,000$10.39$155,850.00View SEC Filing  
10/21/2013Paul B ClevelandDirectorSell10,000$10.93$109,300.00View SEC Filing  
10/15/2013Edward O Lanphier IICEOSell25,000$11.32$283,000.00View SEC Filing  
10/10/2013Henry Ward WolffCFOSell10,000$11.28$112,800.00209,219View SEC Filing  
10/1/2013Philip D GregoryVPSell15,000$10.54$158,100.00View SEC Filing  
9/16/2013Edward Lanphier IICEOSell25,000$11.29$282,250.00330,000View SEC Filing  
9/10/2013Henry Ward WolffCFOSell10,000$10.86$108,600.00View SEC Filing  
9/3/2013Paul ClevelandDirectorSell7,278$10.30$74,963.40View SEC Filing  
9/3/2013Philip GregoryVPSell15,000$10.33$154,950.0090,000View SEC Filing  
8/26/2013Dale AndoCMOSell15,000$10.04$150,600.0084,798View SEC Filing  
8/15/2013Edward Lanphier IICEOSell25,000$10.12$253,000.00330,000View SEC Filing  
8/13/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00209,219View SEC Filing  
8/1/2013Philip GregoryVPSell15,000$9.89$148,350.0090,000View SEC Filing  
7/29/2013Philip D GregoryVPSell15,000$10.04$150,600.00View SEC Filing  
7/26/2013Dale G AndoCMOSell15,000$10.09$151,350.00View SEC Filing  
7/17/2013Edward O Lanphier IICEOSell25,000$10.00$250,000.00View SEC Filing  
7/17/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
7/15/2013Paul B ClevelandDirectorSell8,000$9.59$76,720.00View SEC Filing  
6/3/2013Philip D GregoryVPSell3,000$7.88$23,640.00View SEC Filing  
5/28/2013Dale G AndoCMOSell15,000$8.32$124,800.00View SEC Filing  
4/10/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
12/26/2012Dale G AndoCMOSell17,000$5.92$100,640.00View SEC Filing  
12/3/2012John William LarsonDirectorSell15,000$5.64$84,600.00View SEC Filing  
9/5/2012Dale G AndoCMOSell15,000$5.60$84,000.00View SEC Filing  
9/4/2012John William LarsonDirectorSell15,000$5.30$79,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sangamo Therapeutics (NASDAQ SGMO) News Headlines

Source:
DateHeadline
Sangamo Therapeutics Inc (SGMO) Short Interest Up 20.7% in AprilSangamo Therapeutics Inc (SGMO) Short Interest Up 20.7% in April
www.americanbankingnews.com - April 26 at 2:22 AM
Watch CRISPR Therapeutics (CRSP)Watch CRISPR Therapeutics (CRSP)
www.baystreet.ca - April 25 at 8:28 AM
Sangamo Therapeutics (SGMO) Commences $200M Public Offering of Common StockSangamo Therapeutics (SGMO) Commences $200M Public Offering of Common Stock
www.streetinsider.com - April 25 at 8:28 AM
$36.08 Million in Sales Expected for Sangamo Therapeutics Inc (SGMO) This Quarter$36.08 Million in Sales Expected for Sangamo Therapeutics Inc (SGMO) This Quarter
www.americanbankingnews.com - April 25 at 5:56 AM
Your Guide to Investing in Zinc-Finger (ZFN) Gene EditingYour Guide to Investing in Zinc-Finger (ZFN) Gene Editing
finance.yahoo.com - April 24 at 5:28 PM
Sangamo Therapeutics Announces Proposed Public Offering of Common StockSangamo Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - April 24 at 5:28 PM
Sangamo Therapeutics shares fall on announced secondary offeringSangamo Therapeutics shares fall on announced secondary offering
finance.yahoo.com - April 24 at 5:28 PM
Sangamo Therapeutics Inc (SGMO) Expected to Post Earnings of -$0.05 Per ShareSangamo Therapeutics Inc (SGMO) Expected to Post Earnings of -$0.05 Per Share
www.americanbankingnews.com - April 23 at 1:14 AM
BRIEF-Sangamo Therapeutics Says Co Announced A Data Security Incident Involving Compromise Of A Senior ...BRIEF-Sangamo Therapeutics Says Co Announced A Data Security Incident Involving Compromise Of A Senior ...
www.reuters.com - April 19 at 5:31 PM
Reader Inquiry: Is Recent Weakness In Sangamo Therapeutics A Buying Opportunity?Reader Inquiry: Is Recent Weakness In Sangamo Therapeutics A Buying Opportunity?
seekingalpha.com - April 19 at 8:26 AM
Insider Selling: Sangamo Therapeutics Inc (SGMO) CFO Sells 5,000 Shares of StockInsider Selling: Sangamo Therapeutics Inc (SGMO) CFO Sells 5,000 Shares of Stock
www.americanbankingnews.com - April 18 at 4:10 PM
Curt A. Herberts III Sells 8,163 Shares of Sangamo Therapeutics Inc (SGMO) StockCurt A. Herberts III Sells 8,163 Shares of Sangamo Therapeutics Inc (SGMO) Stock
www.americanbankingnews.com - April 17 at 7:28 PM
Sangamo Therapeutics Inc (SGMO) Given Consensus Recommendation of "Buy" by AnalystsSangamo Therapeutics Inc (SGMO) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 15 at 11:29 AM
Has Sangamo Therapeutics Inc (NASDAQ:SGMO) Improved Earnings Growth In Recent Times?Has Sangamo Therapeutics Inc (NASDAQ:SGMO) Improved Earnings Growth In Recent Times?
finance.yahoo.com - April 13 at 8:35 AM
Markets Recovering From Latest Trump TweetstormMarkets Recovering From Latest Trump Tweetstorm
finance.yahoo.com - April 11 at 5:19 PM
Sangamo Therapeutics (SGMO) Upgraded at ValuEngineSangamo Therapeutics (SGMO) Upgraded at ValuEngine
www.americanbankingnews.com - April 10 at 7:17 PM
Insider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells 5,000 Shares of StockInsider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells 5,000 Shares of Stock
www.americanbankingnews.com - April 9 at 7:35 PM
Biotech Fire Sale: 2 Top Stocks to Buy Next WeekBiotech Fire Sale: 2 Top Stocks to Buy Next Week
finance.yahoo.com - April 8 at 9:42 AM
Ready for the Next Wave of the Biotech Bull?Ready for the Next Wave of the Biotech Bull?
www.nasdaq.com - April 6 at 5:31 PM
Wired News – Sangamo Therapeutics’ Preclinical Study Data from MPS II in Vivo Genome Editing Program Published in Molecular TherapyWired News – Sangamo Therapeutics’ Preclinical Study Data from MPS II in Vivo Genome Editing Program Published in Molecular Therapy
finance.yahoo.com - April 6 at 8:40 AM
 Analysts Anticipate Sangamo Therapeutics Inc (SGMO) to Post -$0.05 Earnings Per Share Analysts Anticipate Sangamo Therapeutics Inc (SGMO) to Post -$0.05 Earnings Per Share
www.americanbankingnews.com - April 6 at 3:08 AM
Curt A. Herberts III Sells 2,278 Shares of Sangamo Therapeutics Inc (SGMO) StockCurt A. Herberts III Sells 2,278 Shares of Sangamo Therapeutics Inc (SGMO) Stock
www.americanbankingnews.com - April 4 at 11:36 PM
Steven J. Mento Sells 7,215 Shares of Sangamo Therapeutics Inc (SGMO) StockSteven J. Mento Sells 7,215 Shares of Sangamo Therapeutics Inc (SGMO) Stock
www.americanbankingnews.com - April 4 at 11:17 PM
Crash Protection Kicks In For Universal DisplayCrash Protection Kicks In For Universal Display
seekingalpha.com - April 4 at 4:05 PM
Sangamo Announces Publication In Molecular Therapy Of Preclinical Study Data From MPS II In Vivo Genome Editing ProgramSangamo Announces Publication In Molecular Therapy Of Preclinical Study Data From MPS II In Vivo Genome Editing Program
finance.yahoo.com - April 4 at 8:31 AM
Sangamo Therapeutics (SGMO) Upgraded to "Buy" at ValuEngineSangamo Therapeutics (SGMO) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - April 3 at 12:30 AM
BidaskClub Downgrades Sangamo Therapeutics (SGMO) to HoldBidaskClub Downgrades Sangamo Therapeutics (SGMO) to Hold
www.americanbankingnews.com - March 29 at 3:36 PM
Sangamo Therapeutics (SGMO) Downgraded to Hold at BidaskClubSangamo Therapeutics (SGMO) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - March 27 at 4:34 PM
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Sangamo Therapeutics, Inc. Investors (SGMO) - Business Wire (press release)Glancy Prongay & Murray LLP Announces Investigation on Behalf of Sangamo Therapeutics, Inc. Investors (SGMO) - Business Wire (press release)
www.businesswire.com - March 22 at 5:28 PM
Today’s Research Reports on Trending Tickers: Global Blood Therapeutics and Sangamo TherapeuticsToday’s Research Reports on Trending Tickers: Global Blood Therapeutics and Sangamo Therapeutics
finance.yahoo.com - March 22 at 8:38 AM
Sangamo Therapeutics Inc (SGMO) Expected to Post Quarterly Sales of $36.08 MillionSangamo Therapeutics Inc (SGMO) Expected to Post Quarterly Sales of $36.08 Million
www.americanbankingnews.com - March 22 at 6:54 AM
Sangamo Therapeutics Inc (SGMO) Receives Average Recommendation of "Buy" from AnalystsSangamo Therapeutics Inc (SGMO) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 21 at 11:39 AM
Sangamo Therapeutics Inc (NASDAQ:SGMO): Set To Experience A Decrease In Earnings?Sangamo Therapeutics Inc (NASDAQ:SGMO): Set To Experience A Decrease In Earnings?
finance.yahoo.com - March 20 at 5:09 PM
Sangamo Therapeutics Inc (SGMO) Expected to Announce Earnings of -$0.05 Per ShareSangamo Therapeutics Inc (SGMO) Expected to Announce Earnings of -$0.05 Per Share
www.americanbankingnews.com - March 20 at 3:17 AM
Sangamo Therapeutics (SGMO) Lowered to "Buy" at BidaskClubSangamo Therapeutics (SGMO) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - March 17 at 6:22 AM
Kathy Yi Sells 5,000 Shares of Sangamo Therapeutics Inc (SGMO) StockKathy Yi Sells 5,000 Shares of Sangamo Therapeutics Inc (SGMO) Stock
www.americanbankingnews.com - March 16 at 10:29 PM
3 Reasons CRISPR Stocks Could Keep Soaring3 Reasons CRISPR Stocks Could Keep Soaring
finance.yahoo.com - March 16 at 8:30 AM
Wedbush Comments on Sangamo Therapeutics Incs Q1 2018 Earnings (SGMO)Wedbush Comments on Sangamo Therapeutics Inc's Q1 2018 Earnings (SGMO)
www.americanbankingnews.com - March 16 at 7:56 AM
Fate Therapeutics (FATE) and Sangamo Therapeutics (SGMO) Financial ContrastFate Therapeutics (FATE) and Sangamo Therapeutics (SGMO) Financial Contrast
www.americanbankingnews.com - March 16 at 5:23 AM
Sangamo Therapeutics (SGMO) Stock Rating Reaffirmed by WedbushSangamo Therapeutics (SGMO) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - March 13 at 6:22 PM
Sangamo Therapeutics Part III: Elucidating The Prospects Of Amyotrophic Lateral Sclerosis - Seeking AlphaSangamo Therapeutics Part III: Elucidating The Prospects Of Amyotrophic Lateral Sclerosis - Seeking Alpha
seekingalpha.com - March 10 at 8:32 AM
Sangamo Therapeutics - Part I: Does Zinc Finger Nuclease Have A Shot? - Seeking AlphaSangamo Therapeutics - Part I: Does Zinc Finger Nuclease Have A Shot? - Seeking Alpha
seekingalpha.com - March 8 at 8:34 AM
Sangamo Therapeutics Announces Presentations At Upcoming Investor Conferences - PR Newswire (press release)Sangamo Therapeutics Announces Presentations At Upcoming Investor Conferences - PR Newswire (press release)
www.prnewswire.com - March 6 at 8:26 AM
Sangamo Therapeutics Inc (SGMO) Director Sells $219,505.91 in StockSangamo Therapeutics Inc (SGMO) Director Sells $219,505.91 in Stock
www.americanbankingnews.com - March 5 at 9:31 PM
Sangamo Therapeutics Inc (SGMO) VP Curt A. Herberts III Sells 15,000 SharesSangamo Therapeutics Inc (SGMO) VP Curt A. Herberts III Sells 15,000 Shares
www.americanbankingnews.com - March 5 at 9:30 PM
State of Wisconsin Investment Board Buys 30,200 Shares of Sangamo Therapeutics Inc (SGMO)State of Wisconsin Investment Board Buys 30,200 Shares of Sangamo Therapeutics Inc (SGMO)
www.americanbankingnews.com - March 5 at 1:56 PM
Sangamo Therapeutics Inc (SGMO) Shares Sold by Sanctuary Wealth Advisors LLCSangamo Therapeutics Inc (SGMO) Shares Sold by Sanctuary Wealth Advisors LLC
www.americanbankingnews.com - March 5 at 12:49 PM
Technical Perspectives on Biotech Stocks -- PTC Therapeutics, Regeneron Pharma, Ritter Pharma, and Sangamo ... - PR Newswire (press release)Technical Perspectives on Biotech Stocks -- PTC Therapeutics, Regeneron Pharma, Ritter Pharma, and Sangamo ... - PR Newswire (press release)
www.prnewswire.com - March 5 at 8:31 AM
$37.91 Million in Sales Expected for Sangamo Therapeutics Inc (SGMO) This Quarter$37.91 Million in Sales Expected for Sangamo Therapeutics Inc (SGMO) This Quarter
www.americanbankingnews.com - March 4 at 2:20 AM
Sangamo Therapeutics, Inc. Reports Inducement Grant Under ... - PR Newswire (press release)Sangamo Therapeutics, Inc. Reports Inducement Grant Under ... - PR Newswire (press release)
www.prnewswire.com - March 3 at 6:15 PM

SEC Filings

Sangamo Therapeutics (NASDAQ:SGMO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sangamo Therapeutics (NASDAQ:SGMO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sangamo Therapeutics (NASDAQ SGMO) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.